DOCSLIB.ORG

Novel Psychoactive Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

7/25/2015 49th Annual Meeting Disclosure I do not have a vested interest in or affiliation with any corporate organization offering financial Novel Psychoactive Substances: support or grant monies for this continuing education “Coming soon to an Emergency Department Near You” activity, or any affiliation with an organization whose philosophy could potentially bias my presentation Patrick Aaronson, PharmD, DABAT [email protected] Clinical Pharmacist - Emergency Medicine UF Health - Jacksonville Clinical Assistant Professor, College of Pharmacy OWNING CHANGE: Taking Charge of Your Profession Objectives: Pharmacist Objectives: Technician 1. Describe emerging drugs of abuse 1. List the new emerging drugs of abuse 2. Examine mechanisms of action and clinical effects 2. Describe the pharmacological and clinical effects of for the newer drugs of abuse new drugs of abuse 3. Explore treatment options and supportive care for patients presenting with acute illicit drug intoxication/overdose Common References for Discussion Topics Novel Psychoactive Substances (NPS) NBOMe’s Excited Delirium Methoxetamine and Methoxphenidine Poisindex® 1 7/25/2015 Novel Psychoactive Substances (NPS) “New Things” Clandestine labs (precursor materials) Rebranding Manufacturing capacity (batch size) Different formulations Delivery Vehicles (spiked consumer products) New Combos Analogs Marketing: (websites / search engines) Drug distributors: drug cartels / Gangs Drug distributors: websites www.lycaeum.org www.erowid.org www.dancesafe.org Adapted from: Peredy, TR. “Emerging Drugs of Abuse: Finding the Adapted from: Peredy, TR. “Emerging Drugs of Abuse: Finding the Reality” North American Congress of Clinical Toxicology, New Reality” Orleans, LA. 20 Oct. 2014 North American Congress of Clinical Toxicology, New Pictures to the right: http://www.businessinsider.com/what-is-synthetic-marijuana- Orleans, LA. 20 Oct. 2014 2015-5?op=1 Novel Psychoactive Substances (NPS) Emerging Drugs of Abuse European Epidemiology Emergency Department Visits Poison Centers Media Surveys www.monitoringthefuture.org DEA Emerging Trends www.drugabuse.gov/drugs-abuse/emerging-trends Pooled urine? (United Kingdom) Sewage-based epidemiology QJM. 2013 Feb;106(2):147-52 Clin Toxicol (Phila). 2014 Mar;52(3):160-5 Adapted from: Wood, DM. “NPS What is the Harm” Drug Test Anal. 2015 Feb 6 North American Congress of Clinical Toxicology, New Orleans, LA. 20 Oct. 2014 Hallucinogens NBOMe: characteristics Blotting paper, powder, liquid, IV MDMA 2CB 25I NBOMe 1 Route: Most common: Oral / Sublingual (6-12 hrs) “N-Bomb” Injection, vaginally, rectally, smoked “Smiles” Detected: “Solaris” Liquid chromatography with mass spectrometry 2 “Holland Film” n = 582 (42% drug source was website) “Boom” “Pandora” 1: Biomed Res Int. 2014;2014:734749 NBOMe 1: Neuropharmacology 2014; 77:200-207 2: J Psychopharmacol. 2014 Aug;28(8):780-8 Biomed Res Int. 2014;2014:734749 Right Picture: https://www.erowid.org/chemicals/nbome/nbome_article1.shtml 2 7/25/2015 NBOMe: Proposed Mechanism NBOMe Clinical Effects 2013 – 2015 Case Series / Reports Highly potent 5HT 2A receptor agonist Duration of Clinical effects: 10 hrs – 13 days Serotonergic tone Moderate to Serious Outcomes: n ~ 50 Most Common Agitation Aggression Tachycardia Hyperpyrexia Hallucinogenic Hallucinations Hypertensive Delirium (Excited Delirium) Seizures Rhabdomyolysis ↑ CK Mydriasis gran mal Renal Injury Alpha-adrenergic agonist, Inhibit reuptake of monoamines (DA, NE, 5HT) Coma Metabolic Amnesia Deaths (9) acidosis Sympathomimetic Agitation and Physical Aggression Least Common Leukocytosis Acute lung Lower Extremity Serotonin failure rigidity Syndrome Hyperthermia, metabolic acidosis, rhabdomyolysis Clin Toxicol (Phila). 2013 Mar;51(3):174-7, Clin Toxicol (Phila). 2013 Jul;51(6):487-92, Drug Test Anal. 2014 Jul-Aug;6(7-8):764-9, Forensic Sci Int. 2014 Jan;234:e14-20, Am J Forensic Med Pathol. 2014 Mar;35(1):20-5, J Psychopharmacol. 2014 Aug;28(8):780-8., Med Klin Intensivmed Notfmed. 2014 May;109(4):271-5., Clin Toxicol (Phila). 2014 Jun;52(5):561-5, Drug Clin Toxicol (Phila). 2014 Jun;52(5):561-5 Chem Toxicol. 2015 Jan;38(1):113-9, Am J Emerg Med. 2014 Nov;32(11):1444.e3-5, Biomed Res Int. 2014;2014:734749, J Addict Dis. 2014;33(3):196-201, J Med Toxicol. 2014 Nov J Med Toxicol. 2014 Nov 12 12, Psychosomatics. 2015 Mar-Apr;56(2):129-39, Forensic Sci Int. 2015 Jun;251:e1-8. Eur J Pharmacol 2007 559:132–137 NBOMe Exposures Florida 2015 Excited delirium 4 cases Delirium with agitation Ages 14 – 17 y/o Violence, hyperactivity, and hyperthermia Clinical Effects Agitation / irritable Result: Sudden and unexpected cardiopulmonary Hallucinations / delusions arrest Seizures Fever / hyperthermia Pathophysiology: abnormal dopamine processing Hypertension / tachycardia Unable to compensate for rapid increase in dopamine Rhabdomyolysis Renal Failure levels J Med Toxicol. 2013 9:172-178 J Emerg Med 2012 43:897–905 FPICN Query Builder Arch Gen Psychiatry 1998 55:793–799 Ann Neurol 1996 40:428-430 Phencyclidine and Ketamine: Epidemiology U.S. Dissociatives Ketamine1,2 Health Care Facility Moderate to Severe Outcomes - Ketamine 2012 150 67 2013 147 68 - Phencyclidine - Methoxetamine Phencyclidine1,2 Health Care Facility Moderate to Severe Outcomes - Methoxphenidine 2012 348 183 2013 282 140 1ClinicalToxicology 2013; 51:949 -1229 2ClinicalToxicology 2014; 52:1032 - 1283 3 7/25/2015 Arycyclohexylamines (Dissociatives) Clinical Manifestations: Dissociatives Pathophysiology Common Findings 2 Nystagmus , blank stare (diplopia) “Dissociate" the somatosensory cortex from higher centers 1 Lack of response to external stimuli (Dissociated) NMDA receptor antagonists psychosis, analgesia, anesthesia Hypertension 3 Inhibit biogenic amine reuptake sympathomimetic Violent/agitated/bizarre behavior Concentrations Stimulation of sigma receptors coma Hallucinations / delusions Drug 4 Higher concentrations associated with death Rhabdomyolysis renal failure Nicotinic Large Doses coma Increasing Cholinergic Opioid 1Adv Exp Med Biol. 1990;268:27-33 2Anesth Analg. 1966;45:29-40 Ann Emerg Med. 1981;10:237-242 3Synapse. 1991;8:289-300 4Brain Res. 1978;152:176-182 Clinical Manifestations: Neuropsychiatric Dissociatives Hallmark of PCP – delusion of “superhuman strength” Ketamine Methoxetamine Invulnerability Jumping MXE Fighting large crowds or police Mexxy Self mutilation MKet Ketamine Arch Intern Med 1992; 152:859-860 Methoxetamine Methoxetamine Methoxetamine Clinical Effects Characteristics Ketamine analog (Dissociative) 2011 – 2015 Case Series / Reports Moderate to Severe Outcomes: (n ~ 15) Slower onset / longer duration than ketamine Most Common Dissociative Hallucinations Catatonic Rotary NMDA receptor antagonist, Serotonin agonist, Dopamine Psychosis Nystagmus reuptake inhibition Agitation Mydriasis Tachycardia / Stupor Hypertensive Route: Oral, Insufflation, IM, IV, Rectal Cerebellar Amnesia Deaths (4) Detected: ataxia Coma Reparatory Hyperthermia Rhabdomyolysis Liquid chromatography Failure With mass spectrometry Least Common Acute Renal and ↑ Creatinine Hyponatremia Seizures Liver failure Kinase FPICN Query Builder, Clin Toxicol (Phila). 2011 Nov;49(9):874-5., Eur J Clin Pharmacol. 2012 May;68(5):853-6, Ann Emerg Med. 2012 Jul;60(1):97-9, Clin Toxicol (Phila). 2012 Jun;50(5):438-40, Med Hypotheses. 2012 Oct;79(4):504-7. , J Anal Toxicol. 2013 Jan-Feb;37(1):43-6, Emerg Med J. 2014 Jan;31(1):45-7. , Neurosci Ther. 2013 Jun;19(6):454-60 , Picture to the right: Przegl Lek. 2013;70(8):671-3., Ned Tijdschr Geneeskd. 2014;158, J Anal Toxicol. 2014 Sep;38(7):410-5. Int J Occup Med Environ Health. 2014 Aug;27(4):683-90, J Forensic Sci. 2015 Jan;60 Suppl 1:S264-8., philadelphia.cbslocal.com/2014/01/17/customs-officials- seize-dangerous-drug-at-philadelphia-ups-facility CNS Neurosci Ther. 2013 Jun;19(6):454-60 Clin Toxicol (Phila). 2011 Nov;49(9):874-5. 4 7/25/2015 Methoxphenidine / Diphenidine Dissociatives Characteristics Phencyclidine Methoxphenidine Route: nasal, IV, smoked (vaporized), rectal Oral (“bombed”) in ∼50–150 mg doses MXP Onset delayed ~ 1 hr (risk for overdosing) Phencyclidine Duration: 3 – 7 hrs PCP Detected: Liquid chromatography with mass spectrometry Methoxphenidine Clin Toxicol (Phila). 2015 Jun;53(5):446-53 Methoxphenidine Clinical Effects Legal High? 2014 Case Series Federal Schedule State Schedule n = 14 (diphenidine), n = 3 (methoxphenidine) 25I NBOMe Temporary Schedule I FL, GA, LA, VA Hallucinations Disoriented Anxiety Dissociation 25B NBOMe Coma (n=3) Agitated 20% 25C NBOMe Mydriasis Nystagmus Tachycardia Hypertension Horizontal and Vertical Methoxetamine Not Federally Regulated Al, AZ, FL, IN, LA, MN, ND, OH, VA, UT Urinary Retention Muscle Rigidity Prolonged activated partial Methoxphenidine Not Federally Regulated Not Regulated thromboplastin time (n=2) Clin Toxicol (Phila). 2015 Jun;53(5):446-53 J Anal Toxicol. 2015 May;39(4):287-93 Fed Regist. 2014 Mar 7;79(45):12938-43 Clin Toxicol (Phila). 2014 Dec;52(10):1288-91 Treatment Primarily supportive Management: Clinical Pearls Hallucinogens and Dissociatives Think about adulterants Quiet supportive environment Hydration, sedation, quiet environment (minimal stimuli) Agitation (“bad trip”) “talking the patient down” Benzodiazepines www.emsworld.com/article/10324064/ 5 7/25/2015 Treatment Treatment: Excited delirium Benzodiazepines: Seizures, Agitation Rapid sedation, IV fluids, decrease hyperthermia Caution
Recommended publications
  • FSI-D-16-00226R1 Title

    FSI-D-16-00226R1 Title

    Elsevier Editorial System(tm) for Forensic Science International Manuscript Draft Manuscript Number: FSI-D-16-00226R1 Title: An overview of Emerging and New Psychoactive Substances in the United Kingdom Article Type: Review Article Keywords: New Psychoactive Substances Psychostimulants Lefetamine Hallucinogens LSD Derivatives Benzodiazepines Corresponding Author: Prof. Simon Gibbons, Corresponding Author's Institution: UCL School of Pharmacy First Author: Simon Gibbons Order of Authors: Simon Gibbons; Shruti Beharry Abstract: The purpose of this review is to identify emerging or new psychoactive substances (NPS) by undertaking an online survey of the UK NPS market and to gather any data from online drug fora and published literature. Drugs from four main classes of NPS were identified: psychostimulants, dissociative anaesthetics, hallucinogens (phenylalkylamine-based and lysergamide-based materials) and finally benzodiazepines. For inclusion in the review the 'user reviews' on drugs fora were selected based on whether or not the particular NPS of interest was used alone or in combination. NPS that were use alone were considered. Each of the classes contained drugs that are modelled on existing illegal materials and are now covered by the UK New Psychoactive Substances Bill in 2016. Suggested Reviewers: Title Page (with authors and addresses) An overview of Emerging and New Psychoactive Substances in the United Kingdom Shruti Beharry and Simon Gibbons1 Research Department of Pharmaceutical and Biological Chemistry UCL School of Pharmacy
  • Acute Toxicity Associated with the Recreational Use of the Novel Dissociative Psychoactive Substance Methoxphenidine

    Acute Toxicity Associated with the Recreational Use of the Novel Dissociative Psychoactive Substance Methoxphenidine

    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2014 Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine Hofer, K E ; Degrandi, C ; Müller, D M ; Zürrer-Härdi, U ; Wahl, S ; Rauber-Lüthy, C ; Ceschi, A Abstract: INTRODUCTION: Methoxphenidine is a novel dissociative designer drug of the diarylethy- lamine class which shares structural features with phencyclidine (PCP), and is not at present subject to restrictive regulations. There is very limited information about the acute toxicity profile of methoxpheni- dine and the only sources are anonymous internet sites and a 1989 patent of the Searle Company. We report a case of analytically confirmed oral methoxphenidine toxicity. CASE DETAILS: A 53-year-old man was found on the street in a somnolent and confusional state. Observed signs and symptoms such as tachycardia (112 bpm), hypertension (220/125 mmHg), echolalia, confusion, agitation, opisthotonus, nys- tagmus and amnesia were consistent with phencyclidine-induced adverse effects. Temperature (99.1°F (37.3°C)) and peripheral oxygen saturation while breathing room air (99%) were normal. Laboratory analysis revealed an increase of creatine kinase (max 865 U/L), alanine aminotransferase (72 U/L) and gamma-glutamyl transpeptidase (123 U/L). Methoxphenidine was identified by a liquid chromatogra- phy tandem mass spectrometry toxicological screening method using turbulent flow online extraction in plasma and urine samples collected on admission. The clinical course was favourable and signs and symptoms resolved with symptomatic treatment. CONCLUSION: Based on this case report and users’ web reports, and compatible with the chemical structure, methoxphenidine produces effects similar to those of the arylcyclohexylamines, as PCP.
  • CREW NPS Booklet

    CREW NPS Booklet

    NEW Psychoactive DRUGS V1.7 05/15 Service availability Drop-in: Monday – Wednesday: 1pm – 5pm, Thursday: 3pm – 7pm, Friday – Saturday: 1pm – 5pm, Sunday: Closed Telephone information and support: Monday – Friday: 10am – 5pm Online information and chatroom support: www.mycrew.org.uk Address | 32 Cockburn Street | Edinburgh | EH1 1PB Telephone | 0131 220 3404 Email | [email protected] Main | www.crew2000.org.uk Enterprise | www.mindaltering.co.uk Info and support | www.mycrew.org.uk Facebook | www.facebook.com/Crew2000 Twitter | www.twitter.com/Crew_2000 Instagram | www.instagram.com/Crew_2000 This booklet has been designed to expand worker knowledge and confidence in the area of NPS. It is most useful when discussed as part of Crew’s NPS training. Crew was established in 1992, in response to the rapid expansion of recreational drug use. We provide up-to-date information on the drugs that people are taking so they can make informed decisions about their own health. This is achieved using a stepped care approach and through collaboration with volunteers, service users and professionals. Crew neither condemns nor condones drug use, but we believe there are ways to reduce harm to health. As a national agency, Crew is at the forefront of emerging drug trends and we engage at all levels including service development, practice and policy. Our services include: – Support line: non-judgmental drug and sexual health information and support. – Drop-in: drug and sexual health information, condoms (NHS c:card service) and DJ workshops. – Outreach services: we provide welfare at large events, such as clubs and festivals to educate revellers on partying safely.
  • Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE

    Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE

    Novel Psychoactive Treatment UK Network NEPTUNE Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE This publication of the Novel Psychoactive Treatment UK Network (NEPTUNE) is protected by copyright. The reproduction of NEPTUNE guidance is authorised, provided the source is acknowledged. © 2015 NEPTUNE (Novel Psychoactive Treatment UK Network) 2015 Club Drug Clinic/CAPS Central and North West London NHS Foundation Trust (CNWL) 69 Warwick Road Earls Court SW5 9HB http://www.Neptune-clinical-guidance.com http://www.Neptune-clinical-guidance.co.uk The guidance is based on a combination of literature review and expert clinical con sensus and is based on information available up to March 2015. We accept no responsi bility or liability for any consequences arising from the use of the information contained in this document. The recommended citation of this document is: Abdulrahim D & Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. Novel Psychoactive Treatment UK Network (NEPTUNE). London, 2015. NEPTUNE is funded by the Health Foundation, an independent charity working to improve the quality of health care in the UK. Editorial production and page design by Ralph Footring Ltd, http://www.footring.co.uk NEPTUNE NEPTUNE (Novel Psychoactive Treatment UK Network): Expert Group members NEPTUNE Expert Group Dr Owen Bowden-Jones Neptune Chair Clinical and programme lead Consultant
  • Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J

    Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Hertfordshire Research Archive Citation for the published version: Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J. M., ... vento, A. (2019). New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues. Current Addiction Reports, 6(2), 140-152. https://doi.org/10.1007/s40429-019-00249-z Document Version: Accepted Version The final publication is available at Springer Nature via https://doi.org/10.1007/s40429-019-00249-z © 2019 Springer Nature Publishing AG General rights Copyright© and Moral Rights for the publications made accessible on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (http://uhra.herts.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge. Take down policy If you believe that this document breaches copyright please contact us providing details, any such items will be temporarily removed from the repository pending investigation.
  • Synthesis, Characterisation and Development of Novel, Validated Methods for the Detection and Quantification of Diphenidine- Derived New Psychoactive Substances

    Synthesis, Characterisation and Development of Novel, Validated Methods for the Detection and Quantification of Diphenidine- Derived New Psychoactive Substances

    Synthesis, characterisation and development of novel, validated methods for the detection and quantification of diphenidine- derived New Psychoactive Substances S M O ALKIRKIT 2020 i Synthesis, characterisation and development of novel, validated methods for the detection and quantification of diphenidine-derived New Psychoactive Substances Soliman Mohamed Omar Alkirkit A thesis submitted in partial fulfilment of the requirements of the Manchester Metropolitan University for the degree of Doctor in Philosophy Department of Natural Sciences Faculty of Science & Engineering, Manchester Metropolitan University 2020 ii Abbreviations and Acronyms AA Ammonium acetate AB-CHMINACA (N-[1-Amino-3-methyl-oxobutan-2-yl]-1- [cyclohexylmethyl]-1H-indazole-3-carboxamide) 2-AI 2-Aminoindane ATR-FTIR Attenuated total reflection- Fourier Transform Infrared Spectroscopy As peak asymmetry BrDP Bromodiphenidine BZP Benzylpiperazine CHMINACA An indole-based synthetic cannabinoid CLDP Chlorodiphenidine COSY Correlation Spectroscopy CYP Cytochrome P450 enzymes Dd Doublet of doublets Ddd Doublet of doublet of doublets DAD Diode-Array Detector DAMP 4-Dimethylaminopyridine DEPT Distortionless Enhancement by Polarization Transfer DET N,N-Diethyltryptamine DIPH Diphenidine DMSO-d6 Dimethyl sulfoxide-d6 DP Diphenidine DPD Diphenidine DPH Diphenidine ii 2-EAPB 2-(2-Ethylaminopropyl) benzofuran EMCDDA European Monitoring Centre for Drugs and Drug Addiction EU European Union EWS Early Warning System ɛ Molar absorptivity FDP Fluorodiphenidine FCEP Fluorocyanoephenidine
  • An Approach to the New Psychoactive Drugs Phenomenon

    An Approach to the New Psychoactive Drugs Phenomenon

    REVIEW ARTICLE An approach to the new psychoactive drugs phenomenon Helen Dolengevich-Segal,1,2 Beatriz Rodríguez-Salgado,3 Jorge Gómez-Arnau,1 Daniel Sánchez-Mateos4 1 Servicio de Psiquiatría, Hospital ABSTRACT Universitario del Henares. Cosla- da, Madrid. Background. The new psychoactive drugs (NPD) are those that represent a danger to public health and are 2 Fundación Psiformación. Madrid. not prohibited by conventions on international narcotics. The concept also includes new contexts and new 3 Centro de Salud Mental de San Blas. Hospital Universitario routes of consumption as well as novel ways of distribution, notably Internet. The risks associated with NPD Ramón y Cajal. Madrid. consumption are largely unknown to users and to health care providers. Objective. To integrate the exist- 4 Hospital Universitario La Fe. Va- ing evidence regarding the main NPD in terms of description, epidemiology, psychopharmacology, medical lencia. complications and psychoactive effects. Method. To review relevant and updated clinical information on NPD Correspondence: obtained from specialized books and indexed scientific journals (PubMed/Medline, Google Scholar, Scopus), Helen Dolengevich-Segal as well as official documents edited by international organizations dedicated to the epidemiologic analysis Servicio de Psiquiatría, Hospital of drug abuse and Internet websites and forums managed by psychoactive substance users. Results. As- Universitario del Henares. pects of clinical and pharmacological interest are described comprehensively, together with epidemiological Avenida de Marie Curie s/n 28822 Coslada, Madrid, España. data and risks associated to the consumption of the most relevant NPD: synthetic cannabinoids, synthetic Phone: (0034) 91191 - 2852. cathinones, NBOMe series, indoleamines, piperazines, hallucinogenic mushrooms (Psilocybe SP.), synthetic E-mail: [email protected] opioids, plant products (khat, kratom, Salvia divinorum, ayahuasca) and dissociative anesthetics.
  • When Good Times Go Bad: Managing 'Legal High' Complications in The

    When Good Times Go Bad: Managing 'Legal High' Complications in The

    Journal name: Open Access Emergency Medicine Article Designation: REVIEW Year: 2018 Volume: 10 Open Access Emergency Medicine Dovepress Running head verso: Caffrey and Lank Running head recto: Legal highs open access to scientific and medical research DOI: http://dx.doi.org/10.2147/OAEM.S120120 Open Access Full Text Article REVIEW When good times go bad: managing ‘legal high’ complications in the emergency department Charles R Caffrey Abstract: Patients can use numerous drugs that exist outside of existing regulatory statutes in Patrick M Lank order to get “legal highs.” Legal psychoactive substances represent a challenge to the emergency medicine physician due to the sheer number of available agents, their multiple toxidromes and Department of Emergency Medicine, Feinberg School of Medicine, presentations, their escaping traditional methods of analysis, and the reluctance of patients to Northwestern University, Chicago, divulge their use of these agents. This paper endeavors to cover a wide variety of “legal highs,” IL, USA or uncontrolled psychoactive substances that may have abuse potential and may result in seri- ous toxicity. These agents include not only some novel psychoactive substances aka “designer drugs,” but also a wide variety of over-the-counter medications, herbal supplements, and even a household culinary spice. The care of patients in the emergency department who have used “legal high” substances is challenging. Patients may misunderstand the substance they have been exposed to, there are rarely any readily available laboratory confirmatory tests for these substances, and the exact substances being abused may change on a near-daily basis. This review will attempt to group legal agents into expected toxidromes and discuss associated common clinical manifestations and management.
  • A New Psychoactive Agent with Ketamine-Like NMDA Receptor Antagonist Properties

    A New Psychoactive Agent with Ketamine-Like NMDA Receptor Antagonist Properties

    Accepted Manuscript Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties Heather Kang, Pojeong Park, Zuner A. Bortolotto, Simon D. Brandt, Tristan Colestock, Jason Wallach, Graham L. Collingridge, David Lodge PII: S0028-3908(16)30339-2 DOI: 10.1016/j.neuropharm.2016.08.004 Reference: NP 6402 To appear in: Neuropharmacology Received Date: 26 July 2016 Revised Date: 3 August 2016 Accepted Date: 5 August 2016 Please cite this article as: Kang, H., Park, P., Bortolotto, Z.A., Brandt, S.D., Colestock, T., Wallach, J., Collingridge, G.L., Lodge, D., Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties, Neuropharmacology (2016), doi: 10.1016/j.neuropharm.2016.08.004. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT EPHENIDINE: A NEW PSYCHOACTIVE AGENT WITH KETAMINE- LIKE NMDA RECEPTOR ANTAGONIST PROPERTIES Heather Kang 1, Pojeong Park 2, Zuner A. Bortolotto 2, Simon D. Brandt 3, Tristan Colestock 4, Jason Wallach 4, Graham L. Collingridge 2.5,6 and David Lodge 2* 1. Centre for Synaptic Plasticity, School of Clinical Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK. 2. Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK.
  • Health Alert Movement 2019: Detroit Electronic Music Festival Hart Plaza Downtown Detroit May 25-28, 2019

    Health Alert Movement 2019: Detroit Electronic Music Festival Hart Plaza Downtown Detroit May 25-28, 2019

    Health Alert Movement 2019: Detroit Electronic Music Festival Hart Plaza Downtown Detroit May 25-28, 2019 In this issue Updates for 2019 .............................................................................................................. 2 Prehospital Concerns ....................................................................................................... 3 Hospital Concerns ............................................................................................................ 4 THC .................................................................................................................................. 5 THC Homologs ................................................................................................................. 5 Stimulants......................................................................................................................... 7 Opioids ........................................................................................................................... 10 GABA-B .......................................................................................................................... 12 NMDA ............................................................................................................................. 13 Inhalants ......................................................................................................................... 14 Other Hallucinogens ......................................................................................................
  • A Review of Ketamine Abuse and Diversion

    A Review of Ketamine Abuse and Diversion

    DEPRESSION AND ANXIETY 33:718–727 (2016) Review A REVIEW OF KETAMINE ABUSE AND DIVERSION ∗ Sean Sassano-Higgins, M.D.,1,2 Dave Baron, D.O.,1,2 Grace Juarez, M.D.,1,2 Neevon Esmaili, M.D.,2 and Mark Gold, M.D.3 Ketamine was discovered in the 1960s and released for public use in 1970. Orig- inally developed as a safer alternative to phencyclidine, ketamine is primarily used in clinical settings for analgesia and sedation. In recent years, other uses have been developed, including pain management and treatment of asthma and depression. Clinical use of ketamine causes dissociation and emergence delirium. These effects have led to recreational abuse. Although death from direct phar- macologic effects appears rare, the disinhibition and altered sensory perceptions caused by ketamine puts users at risk of environmental harm. Ketamine has also been implicated in nonconsensual sexual intercourse. Data continue to build that chronic ketamine use may lead to morbidity. Impairment of memory and persistent dissociative, depressive, and delusional thinking has also been reported with long-term use. Lower urinary tract symptoms, including cystitis have been described. Gastric and hepatic pathology have also been noted, including abnor- mal liver function tests, choledochal cysts and dilations of the common bile duct. S-ketamine, an enantiomer in racemic ketamine, has been shown to be hepato- toxic in vitro. Abstinence from ketamine may reduce the adverse effects of chronic use and is considered the mainstay of treatment. Specialized urine drug testing may be required to detect use, as not all point of care urine drug screens include ketamine.
  • LJMU Research Online

    LJMU Research Online

    LJMU Research Online Wallach, J, Colestock, T, Agramunt, J, Claydon, MDB, Dybek, M, Filemban, N, Chatha, M, Halberstadt, AL, Brandt, SD, Lodge, D, Bortolotto, ZA and Adejare, A Pharmacological characterizations of the 'legal high' fluorolintane and isomers http://researchonline.ljmu.ac.uk/id/eprint/10821/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Wallach, J, Colestock, T, Agramunt, J, Claydon, MDB, Dybek, M, Filemban, N, Chatha, M, Halberstadt, AL, Brandt, SD, Lodge, D, Bortolotto, ZA and Adejare, A (2019) Pharmacological characterizations of the 'legal high' fluorolintane and isomers. Behavioural Processes. ISSN 0376-6357 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ http://researchonline.ljmu.ac.uk/